Our previous studies have demonstrated that ceruloplasmin (CP) dysmetabolism is correlated with Parkinson's disease (PD). However, the causes of decreased serum CP levels in PD patients remain to be clarified. This study aimed to explore the potential association between genetic variants of the CP gene and PD. Clinical features, serum CP levels, and the CP gene (both promoter and coding regions) were analyzed in 60 PD patients and 50 controls. A luciferase reporter system was used to investigate the function of promoter single-nucleotide polymorphisms (SNPs). High-density comparative genomic hybridization microarrays were also used to detect large-scale copy-number variations in CP and an additional 47 genes involved in PD and/or copper/ iron metabolism. The frequencies of eight SNPs (one intronic SNP and seven promoter SNPs of the CP gene) and their haplotypes were signifi cantly different between PD patients, especially those with lowered serum CP levels, and controls. However, the luciferase reporter system revealed no signifi cant effect of the risk haplotype on promoter activity of the CP gene. Neither these SNPs nor their haplotypes were correlated with the Hoehn and Yahr staging of PD. The results of this study suggest that common genetic variants of CP are associated with PD and further investigation is needed to explore their functions in PD.
INTRODUCTION
Parkinson's disease (PD) is an age-related neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra [1] . The presence of Lewy bodies in degenerating dopaminergic neurons seems to be the initial characterization of the pathology of PD. In the core of the Lewy body is the protein α-synuclein which binds iron. Iron seems to be a requisite for the deposition and accumulation of α-synuclein.
Thus, iron might be deposited in a disorderly manner in extrapyramidal structures and result in the tissue damage in PD. However, little is known about the cause of iron deposition in PD.
Ceruloplasmin (CP) is a multi-copper enzyme with ferroxidase function and plays an important role in iron metabolism [2] . CP oxidizes ferrous iron into the ferric form and thus keeps the intracellular level of dangerous ferrous iron to a minimum [3, 4] . Hereditary aceruloplasminemia caused by mutation of the CP gene, resulting in the absence of circulating serum CP, presents with parkinsonism and retinal degeneration due to substantial iron accumulation in the basal ganglia and retina [5] . Patel and colleagues have also demonstrated that increased iron accumulation and free-radical injury occur in the central
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Parkinson's disease; ceruloplasmin; single-nucleotide polymorphism; haplotype; copynumber variation nervous system of Cp -/-mice [6] . Thus, the association between CP and PD has been discussed since the ninth decade of the last century. It has been found that both the CP level and oxidative activity in serum and cerebrospinal fl uid are signifi cantly lower in PD patients than in age-and sex-matched healthy controls [7] [8] [9] [10] [11] [12] [13] . In addition, lower serum CP levels are correlated with a younger age of PD onset [14] .
Furthermore, our previous studies and those of others have demonstrated that decreased serum CP level and oxidative activity specifi cally exacerbate nigral iron deposition in PD patients [15] [16] [17] . However, the causes of the decreased serum CP level in PD remain to be clarifi ed.
As PD often has a hereditary basis and the genetic predisposition is seen as a major contributor to the underlying cause, we carried out this study to elucidate whether CP gene variations are generally found in PD patients and contribute to the decreased levels of CP.
MATERIALS AND METHODS

Patients and Controls
Sixty PD patients were recruited from the Department of Neurology, Zhongshan Hospital, Fudan University. PD was diagnosed by two independent movement-disorder specialists (CJ Zhong and LR Jin) according to the criteria of the United Kingdom Parkinson's Disease Society Brain
Bank for idiopathic PD [19] and the modified version of Hoehn and Yahr [20] . [16] . and those with normal serum CP (≥0.20 g/L, PD NCP ).
This study was approved by the Committee on Medical
Ethics of Zhongshan Hospital, Fudan University, and all participants gave informed consent.
CP Gene Sequencing
Blood samples were collected into EDTA-containing tubes. A QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) was used to extract genomic DNA from the white blood cell fraction. The sequences of all exons, intron-exon boundaries, and the DNase cluster region of the promoter in the CP gene were determined by aligning GenBank with genomic sequence records (NM 000096.1).
The primers are shown in Table 1 . CP amplico ns were obtained by polymerase chain reaction (PCR) amplifi cation and purified by cutting out the DNA band from agarose gel electrophoresis. DNA sequencing was performed on an ABI3730XL automated sequencer, using version City, CA). Sequence data were analyzed using VECTOR NTI Advance 11 software (Invitrogen Corp., Carlsbad, CA).
Plasmid Construction
To construct the CP promoter reporter plasmid, we designed 
Comparative Genomic Hybridization Microarray Analysis
We designed a high-density oligonucleotide-based comparative genomic hybridization (CGH) microarray in the Agilent 8×60K format. Briefl y, we fi rst selected 48 candidate genes associated with PD or iron/copper metabolism.
Using the Agilent eArray online system, we selected 52828 oligonucleotide probes for the 48 candidates and their 150-kb fl anking regions on both sides (Table S1 ). The genomic DNAs extracted from PD patients and sex-matched standard DNAs were fragmented via AluI and RsaI enzyme digestion. DNA was labeled using an Agilent SureTag DNA Labeling Kit (Agilent Technologies, Santa Clara, CA).
Different fluorescent dyes were used for DNA labeling of patient DNA (Cy5-dUTP) and standard DNA (Cy3-dUTP).
The labeled product from each patient was mixed with a standard product before being hybridized onto the Agilent 
Statistical Analysis
Data are presented as mean ± SEM. [21] . Spearman correlation analysis was used to evaluate correlations. The level of signifi cance was assumed to be 5%, and all tests were two-sided. All the statistical analyses were performed with SPSS software (version 18.0).
RESULTS
Characteristics of Study Participants
The average age was 61.52 ± 1.25 years in PD patients and 72.82 ± 0.79 years in controls. The gender ratio was 52% male and 48% female in PD patients, and 40% male and 
CP Gene Variants in PD Patients
The distributions and genotypes of the CP gene SNPs in PD patients and controls are shown in Table 2 . Genotype data were fi rst tested for Hardy-Weinberg equilibrium (HWE) before further genetic analysis. There was no significant deviation from the HWE in either the PD or control group (data not shown). Ten SNPs were found in the intronic and promoter regions of CP: two located at introns (rs3736282 C>T and rs17847023 G>A) and the other eight at the promoter (rs17838831 A>G, rs66508328 G>A, rs67870152
C>T, rs16861642 G>A, rs73020328 T>G, rs11708215 G>A, rs73166855 A>G, and rs66953613 C>T). Moreover, the frequencies of eight SNPs (rs3736282 C>T, rs66508328
G>A, rs67870152 C>T, rs16861642 G>A, rs73020328
T>G, rs11708215 G>A, rs73166855 A>G and rs66953613 C>T) were significantly higher in the PD group than in the control group. Compared with controls, PD patients, especially PD LCP patients, carried higher frequencies of homozygous mutant alleles of rs3736282 TT (P = 0.03 for PD, P = 0.02 for PD LCP ), rs66508328 AA (P = 0.02, P = 0.02), rs67870152 TT (P = 0.02, P = 0.02), rs16861642 AA (P = 0.02, P = 0.02), rs73020328 GG (P = 0.02, P = 0.02), rs11708215 AA (P = 0.02, P = 0.02), rs73166855 GG (P = 0.02, P = 0.02), and rs66953613 TT (P = 0.02, P = 0.02).
To examine the combined effect of these eight SNPs in the CP gene, we performed haplotype analysis (Table   3) , which revealed high LD between the eight SNPs (Fig.1) . The results from haplotype analysis were generally consistent with those from single SNPs; the haplotype defined by the mutant alleles of these eight SNPs (TATAGAGT) was associated with risk for PD, especially PD LCP . For example, the PD patients (15%), especially PD LCP (17.8%), had higher frequencies of TATAGAGT/ TATAGAGT than controls (2%) (P = 0.02, P = 0.02). The distributions of the other CP SNP haplotypes did not differ signifi cantly between patients and controls (Table 3) .
No Association of CP Gene Variants with Hoehn and Yahr Stage and Motor Phenotype
We also analyzed whether the frequencies of SNPs in the (Tables 4 and 5 ).
Promoter Activity of the CP Gene
Since seven of the eight significantly changed SNPs were located in the promoter region of the CP gene, we investigated the function of the promoter SNPs/haplotypes of the CP gene using the luciferase reporter system in U251 and HepG2 cells. We found no signifi cant difference in CP promoter activity between the WT haplotype (GCGTGAC/GCGTGAC) and the mutant haplotype (ATAGAGT/ATAGAGT) in both U251 and HepG2 cells (Fig. 2) . Although the in vitro luciferase reporter assay did not reveal the function of the CP promoter haplotype (ATAGAGT), its potential involvement in gene expression cannot be readily excluded.
No Copy Number Variations of the CP gene in PD Patients
Copy number variations (CNVs), including deletions and duplications, were investigated in 24 PD patients (12 PD LCP and 12 PD NCP ) using high-density oligonucleotide CGH microarrays. Among the 48 candidate genes, we only found compound heterozygous deletions of the PARK2 gene in one PD LCP patient (Fig. 3E) . No CNVs were identified in the other 47 candidate genes, including CP, ATP7A, ATP7B, and ATOX1, which are associated with iron/copper metabolism (Fig. 3A-D) . and hypoceruloplasminemia, as well as iron deposition in the basal ganglia [22] . demonstrates the role of CP in the pathogenesis of PD [12] .
Previous studies from our group and others also demonstrated that decreased serum CP levels are associated with movement disorders, including PD, by disturbing brain iron metabolism [14, 15, 17, 23] . However, less is known about the cause of low serum CP levels in PD patients. In this study, we found that the CP gene in The frequency of D544E differed significantly between PD patients and controls [24] . Another study by Castiglioni CP gene variants seemed to be associated with PD in this study [25] . In another study involving 21 Mexican PD patients and 13 healthy volunteers, Martınez-Hernandez et al. found no D544E mutation of the CP gene in the PD patients [17] .
Thus, the CP gene variants in PD patients are inconsistent in different reports. Compared with these studies, we did not find any exonic variants of the CP gene like those in Martınez-Hernandez's report, but two intronic SNPs (rs3736282 and rs17847023) consistent with Castiglioni's report [25] , as well as eight promoter SNPs. These differences may be explained by the different ethnicity and Human genomic rearrangement can cause CNVs [18] .
Rare CNVs are important genetic causes of human diseases, especially neurological disorders including PD [26] [27] [28] [29] [30] [31] [32] .
Therefore, defining the genetic content and genomic location by high-resolution CNV breakpoint analysis is vital to elucidating the etiology of CNV-associated disorders. The PARK2 gene is a molecular diagnostic test for parkinsonism. Kay et al. reported that a total of 0.95% of controls and 0.86% of patients carry a heterozygous CNV mutation of the PARK2 gene [30] . Thus, there is no compelling evidence for an association of heterozygous pathological states in PD [33] [34] [35] . For instance, miR-133b is involved in PD through regulating the expression of pairedlike homeodomain transcription factor 3 (Pitx3) [36] . Further investigation of the expression of microRNAs that might regulate CP gene expression in PD patients is needed.
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